| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Alzheimer's drug-development pipeline: 2016
|
Cummings, Jeffrey
|
|
2016
|
2 |
4 |
p. 222-232
11 p.
|
article
|
| 2 |
A multicenter, randomized, placebo-controlled trial for cilostazol in patients with mild cognitive impairment: The COMCID study protocol
|
Saito, Satoshi
|
|
2016
|
2 |
4 |
p. 250-257
8 p.
|
article
|
| 3 |
Communication Bridge: A pilot feasibility study of Internet-based speech–language therapy for individuals with progressive aphasia
|
Rogalski, Emily J.
|
|
2016
|
2 |
4 |
p. 213-221
9 p.
|
article
|
| 4 |
Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease
|
Scheltens, Nienke M.E.
|
|
2016
|
2 |
4 |
p. 233-240
8 p.
|
article
|
| 5 |
Measuring informed consent capacity in an Alzheimer's disease clinical trial
|
Guarino, Peter D.
|
|
2016
|
2 |
4 |
p. 258-266
9 p.
|
article
|
| 6 |
Mnemonic strategy training of the elderly at risk for dementia enhances integration of information processing via cross-frequency coupling
|
Dimitriadis, Stavros I.
|
|
2016
|
2 |
4 |
p. 241-249
9 p.
|
article
|
| 7 |
Multiple neuropathologies and dementia in the aging brain: A key role for cerebrovascular disease?
|
Charidimou, Andreas
|
|
2016
|
2 |
4 |
p. 281-282
2 p.
|
article
|
| 8 |
SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy
|
Delay-Goyet, Philippe
|
|
2016
|
2 |
4 |
p. 267-280
14 p.
|
article
|
Journal description